Business
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 – - Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing - - Data bols
About this update from Rani Therapeutics Holdings, Inc.
[{"type":"image","alt":"Rani Therapeutics, LLC","displaySize":"","headline":null,"caption":"Rani Therapeutics, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XWNAoYI1bIyf8QCPVkOpHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eedd36d474bbaf8ede890d5712b0f73a","width":300,"height":150}},"lazy":false},{"type":"text","content":"- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence –","length":188,"tagName":"p"},{"type":"text","content":"- Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 –","length":126,"tagName":"p"},{"type":"text","content":"- Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five weeks of dosing -","length":173,"tagName":"p"},{"type":"text","content":"- Data bolster expanding body of evidence of the RaniPill® platform’s potential to facilitate oral delivery of multiple obesity treatments including previously announced semaglutide -","length":183,"tagName":"p"},{"type":"text","content":"- Phase 1 clinical study for RT-114 for the treatment of obesity expected to initiate in mid- 2025 -","length":100,"tagName":"p"},{"type":"text","content":"SAN JOSE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced pharmacokinetic and pharmacodynamic data from a preclinical study evaluating RT-114, a GLP-1/GLP-2 dual agonist (PG-102). PG-102 delivered orally via the RaniPill® capsule demonstrated comparable bioavailability and weight loss to subcutaneously (SC) injected PG-102 (“SC PG-102”). PG-102 is ProGen Co., Ltd’s (“ProGen”) Fc-fusion protein conjugated GLP-1/GLP-2 dual agonist.","length":619,"tagName":"p"},{"type":"text","content":"“We believe that RT-114 has the potential to be a first-in-class, orally administered GLP-1/GLP-2 dual agonist...